Clinical trials: Residual Disease
AML, Adult
MRD-positive AML Clinical Study
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the…
- Trial name
- NCT07131059
- Testing
- Ivosidenib, Gilteritinib, Venetoclax
- Where
- China
- Volunteers
- 537 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B-cell Acute Lymphoblastic Leukemia
Combination of Inaticabtagene Autoleucel With Autologous Hematopoietic Stem Cell Transplantation for Adolescents or Adults With MRD-Positive B-Cell Acute Lymphoblastic Leukemia in Initial Complete Remission.
Evaluate the safety and efficacy of Inaticabtagene autoleucel combined with autologous hematopoietic stem cell transplantation in adolescents or adults with MRD-positive initial complete remission in B-cell acute lymphoblastic…
- Trial name
- NCT06608732
- Testing
- Inaticabtagene autoleucel
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
B-cell Lymphoma, Hodgkin Lymphoma
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma
This study aims to assess the feasibility of predicting patient outcomes at 1 year and 2 years after the end of first-line treatment using "liquid biopsy" (monitoring of circulating tumor DNA, ctDNA), compared to the currently…
- Trial name
- CELERITY (NCT06744075)
- Testing
- Blood assessment
- Where
- 2 sites in France
- Volunteers
- 108 people
- Sponsor
- Centre Henri Becquerel
Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma
RATIONALE: Vaccines, such as dendritic cell therapy (DC) made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
- Conditions
- Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Adult Diffuse Mixed Cell Lymphoma
- Trial name
- NCT01239875
- Testing
- dendritic cell vaccine therapy, cryotherapy, pneumococcal polyvalent vaccine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Mayo Clinic
Cesarean Scar Defect (Isthmococele), Pelvic Pain
Single-Layer Versus Double-Layer Uterine Closure After Primary Cesarean Section
This study compares two surgical techniques for closing the uterus after cesarean section: single-layer versus double-layer closure.
- Conditions
- Cesarean Scar Defect (Isthmococele), Pelvic Pain, Spotting, Amenorrhea Secondary
- Trial name
- NCT07611331
- Testing
- Double-layer hysterorrhaphy at primary cesarean section, Single-layer hysterorrhaphy at primary cesarean section
- Where
- Tunisia
- Volunteers
- 384 people
- Sponsor
- Hédi Chaker Hospital
Gastric Residual Volume, Preterm Infant
Routine Versus no Assessment of Gastric Residual Volumes in Preterm Infants
The practice of checking gastric residuals is not evidence based. The amount of gastric residual volume (GRV) does not correlate with either feeding intolerance or development of NEC.
- Conditions
- Gastric Residual Volume, Preterm Infant, Feeding Disorder Neonatal
- Trial name
- NCT04062851
- Testing
- No Gastric residual volume monitoring
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- AdventHealth
Breast Cancer
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
This is a Phase II randomized, controlled, open label breast cancer clinical trial. 66 patients will be enrolled. The drugs being studied are hydroxychloroquine (Plaquenil) and abemaciclib (also Verzenio).
- Trial name
- ABBY (NCT04523857)
- Testing
- Abemaciclib, Hydroxychloroquine
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
AML (Acute Myelogenous Leukemia)
VEN+IDAC vs IDAC in AML
This study intends to use a randomized controlled design to compare the MRD-negativw rate and related efficacy and safety of venetoclax combined with intermediate-dose cytarabine (IDAC) versus IDAC in the consolidation treatment…
- Trial name
- NCT07537257
- Testing
- Ventoclax, Cytarabine
- Where
- China
- Volunteers
- 232 people
- Sponsor
- Guangdong Second Provincial General Hospital
Feeding Intolerance, Abdominal Distention
SAFEstart Feeding Intolerance Study Phase II
Feeding intolerance is a common problem in the NICU. Feeding intolerance complicates the hospitalization, lengthens the hospital stay, and adds substantially to the cost of care.
- Conditions
- Feeding Intolerance, Abdominal Distention, Gastric Residual, Emesis and Diarrhea
- Trial name
- NCT00331201
- Testing
- SAFEstart
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Intermountain Health Care, Inc.
Opioid-use Disorder, HIV-1-infection
Anti-retroviral Therapy, Medications for Opioid Use Disorder, Opioids and HIV Infection - Study 1
HIV infection, as well as exposure to opioids (including heroin), are associated with systemic immune activation including increased microbial translocation from the gut.
- Conditions
- Opioid-use Disorder, HIV-1-infection, Immune Activation, Inflammation
- Trial name
- AMOHI-1 (NCT04480554)
- Testing
- Methadone, Buprenorphine/naloxone, XR-Naltrexone
- Where
- 2 sites in United States, Vietnam
- Volunteers
- 78 people
- Sponsor
- University of Pennsylvania
NSCLC, Stage I, II, III
A Prospective Study Investigating the Relationship Between Minimal Residual Disease Detection, Monitoring Frequency, and Prognosis in Non-small Cell Lung Cancer Patients Eligible for Curative Treatment.
Adding immune checkpoint inhibitors or molecularly targeted drugs as adjuvant therapy to curative treatments-such as surgery or chemoradiotherapy-for stage I-III non-small cell lung cancer (NSCLC) has been established as a…
- Trial name
- MRDSEEKER (NCT06854939)
- Where
- Japan
- Volunteers
- 350 people
- Sponsor
- National Cancer Center, Japan
Leukemia
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Bone marrow transplantation may be able to replace immune cells that were destroyed by chemotherapy to kill…
- Trial name
- NCT00002701
- Testing
- busulfan, cyclophosphamide, cytarabine
- Where
- 71 sites in Austria, Belgium and 7 more
- Volunteers
- 750 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Kidney Failure, Chronic
Saving Residual Renal Function Among Haemodialysis Patients Receiving Irbesartan
Angiotensin II receptor blockers (ARB) are known to preserve kidney function among patients with kidney diseases and reduced renal function, but not among haemodialysis patients.
- Trial name
- SAFIR (NCT00791830)
- Testing
- Irbesartan
- Where
- 6 sites in Denmark
- Volunteers
- 82 people
- Sponsor
- University of Aarhus
Prostate Cancer, Breast Cancer
Evaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer
This study will use polysomnography, alongside other methodologies such as questionnaires, actigraphic measurements and salivary melatonin samples used in previous studies to investigate sleep quality in patients with i)…
- Trial name
- SIESTA (NCT04543799)
- Testing
- polysomnography, actigraphy, questionnaires
- Where
- Switzerland
- Volunteers
- 60 people
- Sponsor
- Oncology Institute of Southern Switzerland
Hematologic Malignancy, Acute Leukemia
MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies
This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (TCR α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies.
- Conditions
- Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia
- Trial name
- NCT05735717
- Testing
- Fludarabine, Busulfan, Melphalan
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Chronic Myelogenous Leukemia, BCR/ABL Positive
OPTIM DASATINIB (Optimized Tyrosine Kinase Inhibitors Monotherapy)
This protocol is a multicentric interventional phase II study from the French CML Intergroup (FILMC). The core of the protocol is to explore the efficacy and safety of an optimization strategy consisting in the modulation of the…
- Trial name
- OPTIM-DASA (NCT01916785)
- Testing
- Dasatinib
- Where
- 34 sites in Canada, France
- Volunteers
- 289 people
- Sponsor
- Versailles Hospital
Leukemia, Cancer
WT1 for the Detection of Minimal Residual Disease
The purpose of this study is to determine if WT1 is an adequate measurement of minimal residual disease in leukemic patients.
- Trial name
- NCT00179829
- Testing
- WT 1 Testing
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
Relapse Multiple Myeloma, Refractory Multiple Myeloma
TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM)
This is a Phase 1, open-label dose escalation study evaluating the safety and clinical efficacy of Talquetamab in combination with Belantamab mafodotin for a time-limited interval followed by Belantamab mafodotin and Pomalidomide…
- Trial name
- TaBleMM (NCT07720843)
- Testing
- Talquetamab, Belantamab mafodotin, Pomalidomide
- Volunteers
- 50 people
- Sponsor
- Montefiore Medical Center
Stable Angina
Atorvastatin and Clopidogrel HIgh DOse in Stable Patients With Residual High Platelet Activity
The purpose of this study is to evaluate if high-dose (80mg/day) atorvastatin might exert an adjunctive anti-platelet effect compared to high-dose clopidogrel (150mg/day) in stable patients with high on-treatment reactivity…
- Trial name
- ACHIDO (NCT01335048)
- Testing
- atorvastatin and clopidogrel, Clopidogrel
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Ospedale Misericordia e Dolce
Atrial Fibrillation Paroxysmal, Coronary Artery Disease Without Residual Ischemia
Flecainide Versus Amiodarone in the Cardioversion of Paroxysmal Atrial Fibrillation at the Emergency Department, in Patients With Coronary Artery Disease Without Residual Ischemia
Current guidelines for the cardioversion of paroxysmal Atrial Fibrillation at the Emergency Department do not prioritize between antiarrhythmic agents and do not consider the time taken for successful cardioversion.
- Trial name
- FLECA-ED (NCT05549752)
- Testing
- Flecainide Injectable Solution, Amiodarone Injectable Solution
- Where
- 3 sites in Greece
- Volunteers
- 80 people
- Sponsor
- Hippocration General Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.